Cell Source, Inc. – OTC:CLCS

Cell Source stock price today

$0.36
-0.12
-25%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cell Source stock price monthly change

+59900.00%
month

Cell Source stock price quarterly change

+59900.00%
quarter

Cell Source stock price yearly change

+4.35%
year

Cell Source key metrics

Market Cap
 17.62M
Enterprise value
 26.50M
P/E
 -1.83
EV/Sales
 N/A
EV/EBITDA
 -6.57
Price/Sales
 N/A
Price/Book
 -1.62
PEG ratio
 N/A
EPS
 -0.15
Revenue
 N/A
EBITDA
 -4.38M
Income
 -5.60M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cell Source stock price history

Cell Source stock forecast

Cell Source financial statements

Profit Margin

Cell Source, Inc. (OTC:CLCS): Profit margin
Dec 2022 0 -1.33M
Mar 2023 0 -1.69M
Jun 2023 0 -1.24M
Sep 2023 0 -1.33M
CLCS income statement history
0%
Yield TTM
Cell Source, Inc. (OTC:CLCS): Payout ratio
Payout ratio 0%
Cell Source, Inc. (OTC:CLCS): Dividend Yield
2019 2381087.58%
2020 1508194.21%
2021
2022
2023
CLCS dividends history

Debt to Assets

Cell Source, Inc. (OTC:CLCS): Debt to assets
Dec 2022 409845 13.04M 3182.6%
Mar 2023 232420 14.45M 6218.11%
Jun 2023 362329 15.30M 4224.91%
Sep 2023 248357 16.27M 6554.48%
CLCS balance sheet history

Cash Flow

Cell Source, Inc. (OTC:CLCS): Cash Flow
Dec 2022 -723.27K 0 880K
Mar 2023 -309.61K 0 219.96K
Jun 2023 -1.03M 0 925K
Sep 2023 -279.96K 0 260.55K
CLCS cash flow history

Cell Source alternative data

Cell Source
Employees

Cell Source, Inc. (OTC:CLCS): Employee count
Aug 2023 1
Sep 2023 1
Oct 2023 1
Nov 2023 1
Dec 2023 1
Jan 2024 1
Feb 2024 1
Mar 2024 1
Apr 2024 1
May 2024 1
Jun 2024 1
Jul 2024 1

Cell Source other data

Frequently Asked Questions (FAQ)

  • What's the price of Cell Source stock today?

    One share of Cell Source stock can currently be purchased for approximately $0.36.

  • When is Cell Source's next earnings date?

    Unfortunately, Cell Source's (CLCS) next earnings date is currently unknown.

  • Does Cell Source pay dividends?

    No, Cell Source does not pay dividends.

  • How much money does Cell Source make?

    Cell Source has a market capitalization of 17.62M.

  • What is Cell Source's stock symbol?

    Cell Source, Inc. is traded on the OTC under the ticker symbol "CLCS".

  • What is Cell Source's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cell Source?

    Shares of Cell Source can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cell Source's key executives?

    Cell Source's management team includes the following people:

    • Mr. Itamar Shimrat Chief Executive Officer, Pres, Chief Financial Officer & Director(age: 66, pay: $181,740)

  • How many employees does Cell Source have?

    As Jul 2024, Cell Source employs 1 workers.

  • When Cell Source went public?

    Cell Source, Inc. is publicly traded company for more then 11 years since IPO on 1 May 2014.

  • What is Cell Source's official website?

    The official website for Cell Source is cell-source.com.

  • Where are Cell Source's headquarters?

    Cell Source is headquartered at 57 West 57th Street, New York, NY.

  • How can i contact Cell Source?

    Cell Source's mailing address is 57 West 57th Street, New York, NY and company can be reached via phone at +64 6 416 7896.

Cell Source company profile:

Cell Source, Inc.

cell-source.com
Exchange:

OTC

Full time employees:

1

Industry:

Biotechnology

Sector:

Healthcare

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.

+64 6 416 7896
57 West 57th Street
New York, NY 10019

CIK: 0001569340
ISIN: US15114L1044
CUSIP: 15114L104